Catalent, Inc. (NYSE:CTLT) Receives $55.65 Average PT from Analysts

Catalent, Inc. (NYSE:CTLT) has received an average rating of “Hold” from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $55.65.

CTLT has been the subject of several recent research reports. Barclays increased their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. StockNews.com initiated coverage on Catalent in a research note on Monday. They issued a “sell” rating for the company. Finally, Stephens reissued an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th.

Insider Buying and Selling at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of hedge funds have recently added to or reduced their stakes in CTLT. Lindbrook Capital LLC grew its stake in Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Gladius Capital Management LP bought a new position in shares of Catalent in the third quarter valued at approximately $28,000. GAMMA Investing LLC bought a new position in shares of Catalent in the fourth quarter valued at approximately $33,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Catalent in the second quarter valued at approximately $42,000. Finally, Rakuten Securities Inc. bought a new position in shares of Catalent in the fourth quarter valued at approximately $46,000.

Catalent Trading Up 0.3 %

Shares of CTLT stock opened at $57.30 on Friday. The stock has a market cap of $10.37 billion, a price-to-earnings ratio of -9.39, a PEG ratio of 2.34 and a beta of 1.16. The stock has a 50-day moving average of $55.66 and a 200-day moving average of $54.64. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, equities research analysts forecast that Catalent will post -0.17 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.